The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487743 | PMC |
| http://dx.doi.org/10.1017/ipm.2020.94 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.
EClinicalMedicine
October 2024
Centre for Psychedelic Research, Division of Psychiatry, Department Brain Sciences, Imperial College London, United Kingdom.
Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.
Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.
J Child Adolesc Psychopharmacol
January 2025
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase.
View Article and Find Full Text PDFEfficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.
Psychiatry Res
December 2024
Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of Randomized Placebo-Controlled Clinical Trials (RCTs) registered with PROSPERO was conducted.
View Article and Find Full Text PDFMultidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
Article Synopsis
- The study explored how psilocybin-assisted therapy (PAT) impacts personality traits in people with alcohol use disorder (AUD), hypothesizing it would reduce trait impulsiveness and improve drinking behavior.
- Eighty-four AUD patients were divided into two groups (psilocybin vs. placebo) and assessed for changes in personality traits over time, finding significant personality shifts in the psilocybin group, including reduced neuroticism and increased openness.
- The results indicated that lower impulsiveness correlated with decreased alcohol consumption, particularly among those who drank at risk before treatment, pointing to potential benefits of PAT in addressing both personality and drinking behaviors.
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Am J Psychiatry
January 2025
Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, Md. (Wolfgang); Department of Psychiatry, Uniformed Services University, Bethesda, Md. (Wolfgang, Benedek); Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Wolfgang, Wiechers); Department of Veterans Affairs, Office of Research and Development, Washington, D.C. (McClair, Smyth, Tenhula); Department of Veterans Affairs, Executive Division, National Center for PTSD, White River Junction, Vt. (Schnurr, Holtzheimer); Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, N.H. (Schnurr, Holtzheimer); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco. (Woolley, Wiechers); San Francisco Veterans Affairs Medical Center, San Francisco. (Woolley); Department of Psychiatry, Oregon Health and Science University, Portland, Ore. (Stauffer); Department of Mental Health; VA Portland Health Care System, Portland, Ore. (Stauffer); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Wolf); Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, D.C. (States); Department of Psychiatry, Harvard Medical School, Boston (Bradley); VA Boston Healthcare System, Boston (Bradley); Department of Veterans Affairs, Pharmacy Benefits Management Service, Washington, D.C. (Fuller); Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio (Fuller); Department of Veterans Affairs, Northeast Program Evaluation Center, Office of Mental Health, Washington, D.C. (Hermes); Veterans Health Administration Office of Mental Health, Washington, D.C. (Wiechers).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!